CN106591207B - For express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain application - Google Patents

For express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain application Download PDF

Info

Publication number
CN106591207B
CN106591207B CN201611112189.9A CN201611112189A CN106591207B CN 106591207 B CN106591207 B CN 106591207B CN 201611112189 A CN201611112189 A CN 201611112189A CN 106591207 B CN106591207 B CN 106591207B
Authority
CN
China
Prior art keywords
tem1
aif
recombinant
bacterial strain
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201611112189.9A
Other languages
Chinese (zh)
Other versions
CN106591207A (en
Inventor
陈廷涛
辛洪波
王鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanchang University
Original Assignee
Nanchang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanchang University filed Critical Nanchang University
Priority to CN201611112189.9A priority Critical patent/CN106591207B/en
Publication of CN106591207A publication Critical patent/CN106591207A/en
Application granted granted Critical
Publication of CN106591207B publication Critical patent/CN106591207B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/101Plasmid DNA for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides the applications of the bacterial strain and the bacterial strain of a kind of recombinant single chain antibody for expressing AIF and being integrated with AIF.The characteristic that the technical solution is specifically bound using single-chain antibody T18 and tumor endothelial cell marker molecule TEM1, construct AIF-T18 albumen composition, to realize apoptosis inducing factor AIF to the target administration of tumour cell, its apoptosis-induced effect to tumour cell is promoted.The present invention is integrated with the recombinant plasmid of AIF-T18 expressing gene using pET302 plasmid as vector construction first, is then that host imports recombinant plasmid wherein with prokaryotic expression system E.coli BL21, has obtained with the recombinant bacterial strain for stablizing ability to express.On this basis, the present invention devises efficient protein expression around the characteristic of the recombinant bacterium, and for suitable denaturation, renaturation, purification condition is had matched with protein expressioning product existing for inclusion bodies, to realize effective preparation of AIF-T18.

Description

For express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain Using
Technical field
The present invention relates to technical field of molecular biology, and it is thin in host to be related to gene recombination technology and recombinant plasmid into one Protein expression in born of the same parents, and in particular to a kind of bacterial strain and the bacterial strain of the recombinant single chain antibody for expressing AIF and being integrated with AIF Application.
Background technique
Endosialin (TEM1/CD248) is I type transmembrane protein, the 80.9KDa's for being glycosylated modification by one Protein core district's groups are at modifying the glycoprotein of after ripening about in 175KDa.TEM1 is the human tumor marker found in the recent period One of, it plays an important role to the cell growth angiogenesis infiltration and transfer of tumour.
TEM1 outer portion is by five globular domains (the c-type Lectin domain of N-terminal, sushi spline structure domain and three tables Skin growth factor (EGF) sample repeat) and a mucoprotein sample district's groups at, wherein core protein a large amount of salivas acidification with thrombus adjusting Albumen is similar.For adult tissue, the expression and distribution of TEM1 be such that uterus > glomerulus > fallopian tubal blood vessel > heart and lung > its Hetero-organization;In addition, TEM1 expression quantity is relatively seldom in endothelial progenitor cells.However, TEM1 has high expression in following tumour, Such as sarcoma, brain tumor, breast cancer, cutaneum carcinoma, colon cancer, and experiment shows in oophoroma, the infiltration of TEM1 expression and tumour, Prognosis is closely related.Therefore, TEM1 is not expressed or low expression in normal tissue, and in the highly expressed spy of neoplasm vascularity Point, the potentiality predictive of TEM1 as the target molecules of tumor diagnosis and therapy.
Apoptosis inducing factor (apoptosis inducing factor, AIF), is that one kind is present in mitochondria Conservative flavoprotein between outer membrane can induce Caspase independence cell apoptosis.The AIF gene of people is located at Xq25- 26, the length for transcribing the mRNA generated is 2.4kb, encodes alternative splicing body of the protein there are three different length of generation, Their amino acid number is respectively 613,609 and 326.In addition to inducible Apoptosis, AIF has both the activity of oxidoreducing enzyme.
Permeability duct after stimulation of the cell by specific apoptosis induction signal, on mitochondrial membrane (mitochondrial permeability transition pores, MPTP) is opened, and AIF is allowed to be discharged into from mitochondria Endochylema, and enter nucleus in and another mitochondrial protein endonuclease G (Endo G) together, cause nuclear dna It is aggregated and fragments into the segment of 50kb size.
In mediating apoptosis process, there are two the effects of aspect by AIF: first is that can be used as the starting of Apoptosis because Son, second is that can be used as the direct effect factor of Apoptosis.Under normal conditions, AIF is present in mitochondria, Ke Yiqing Except intracellular free radical to prevent Apoptosis;After cell is by apoptotic stimulus.AIF comes out from mitochondria first, so After be transferred in cytoplasm, be finally transferred in nucleus play promote Apoptosis effect.
Single-chain antibody T18 in the present invention using screening laboratory early period is as bionavigation, and T18 is anti-using yeast The screening of body library isolate can in combination with the high-affinity of the mankind and muroid TEM1, specific single-chain antibody, by realize its with The amalgamation and expression of humanization toxin AIF, realizes the final purpose of apoptosis of tumor cells.
And two big methods of oncotherapy now are first is that with the immunotherapy of antibody, second is that with the chemotherapy of chemicals Based on.Antibody mediated immunity therapy targeting is strong, but since its relative molecular weight is big, limits the treatment effect of solid tumor Fruit.The chemicals of small molecule have cancer cell high-intensitive fragmentation effect, but due to that cannot differentiate normal cell, to normal Cell also has certain lethal effect, and side effect is obvious.Therefore, antibody clinically is proposed for the treatment of cancer The novel therapeutic agent of one kind of drug conjugates (Antibody Drug Conjugates, ADC), is based on monoclonal antibody skill The effect of specific recognition made of art research combines the high-intensitive lethal effect of chemicals, realizes the good of specific killing tumour Good effect.
Summary of the invention
The present invention is directed to be directed to the technological deficiency of the prior art, a kind of recombination for expressing AIF and being integrated with AIF is provided The application of the bacterial strain of single-chain antibody and the bacterial strain, to solve AIF pairs of apoptosis inducing factor of natural structure in the prior art The attack of tumour cell lacks targeting.
Another technical problem to be solved by the present invention is that lacking in the prior art a kind of for the purpose of assigning AIF targeting AIF- single-chain antibody structural integrity method.
The invention solves another technical problem be to obtain the expression base for being integrated with AIF- single-chain antibody compound It is cumbersome to the expression of such plasmid in the prior art, protein expression level is lower in the case where the recombinant plasmid of cause.
The invention solves another technical problem be for AIF prepared by above method and to be integrated with the weight of AIF Group single-chain antibody, lack in the prior art it is a kind of verifying its to tumor cell specific binding ability and to tumor cytotoxicity imitate The technological means of fruit.
To realize the above technical purpose, the invention adopts the following technical scheme:
A kind of bacterial strain of the recombinant single chain antibody for expressing AIF and being integrated with AIF, which prepared by following methods :
1) take sequence Aif expressing gene as shown in SEQ ID No.1, sequence as shown in SEQ ID No.2 respectively Aif-T18 expressing gene is connect by digestion mode with pET302 plasmid respectively, respectively obtain recombinant plasmid pET302-Aif, pET302-Aif-T18;
2) step 1) resulting recombinant plasmid pET302-Aif, pET302-Aif-T18 are taken respectively, are transferred to E.coli respectively In BL21, respectively obtain recombinant bacterium pET302-Aif-B21 and pET302-Aif-T18-B21, it is as described for express AIF and It is integrated with the bacterial strain of the recombinant single chain antibody of AIF.
Meanwhile the method for preparing AIF the present invention provides application above-mentioned bacterial strains and being integrated with the recombinant single chain antibody of AIF, The following steps are included:
A bacterial strain described in claim 1) is taken to access in LB culture medium with ampicillin, 35~39 DEG C of shake culture mistakes Night;
B step A) is taken) obtained bacterium solution is cultivated, it is seeded to the inoculum concentration of 3~7% (v/v) in fresh LB culture medium, Culture to bacterium solution OD value is 0.6~0.8, and inducer IPTG to 0.8~1.2mM of final concentration is added, and is then shaken in 35~39 DEG C Cultivate 3~5h;
C it) is separated by solid-liquid separation and takes precipitating, thallus is resuspended in the Binding Buffer that 20~25mL is added, and ultrasonication is then solid Liquid separation takes precipitating;
D inclusion body) is collected from the step C) sediment, the Binding Buffer resuspension that 20~25mL is added is forgiven Body;
E step D) is taken) resulting solubilization of inclusion bodies is in albuminous degeneration liquid, until wherein final concentration of the 30 of inclusion body protein ~50mg/ml, room temperature shake 3~5h, are then centrifuged 25~35min with the revolving speed of 12000~14000rpm, supernatant are taken, by it It is added with the volume ratio of 1:80~1:120 into protein renaturation liquid, under agitation, keeps 36~48h in 2~6 DEG C of environment, It mixes with His beads by the volume ratio of 1:3~1:5 after concentration, is then washed using the imidazole solution that concentration is 450~550mM De- albumen recycles PBS solution dialysis.
Preferably, step A) and step C) described in shake culture be revolving speed shaking table culture with 150~250rpm.
Preferably, step B) in for the IPTG that is added into bacterium solution be IPTG that concentration is 1M, by 1/1000 ratio Example is added into the bacterium solution.
Preferably, step C) described in ultrasonication condition are as follows: every ultrasonic treatment 5s stops 8s, so repeat 95 times, Power is 200W, 2 circulations, it is further preferred that the stop condition of ultrasonication are as follows: bacterium solution becomes less viscous thick, more limpid When stop it is broken.
Preferably, step C) in second condition being separated by solid-liquid separation are as follows: the revolving speed centrifugation 8 of 8000~12000rpm~ 12min.It is further preferred that step C) in second be separated by solid-liquid separation after resulting supernatant collection it is whole to 50mL centrifuge tube, in 4 DEG C save.
Preferably, step D) described in collect inclusion body, be first to be washed with Triton X-100/EDTA Solution Precipitating, it is inclusion body that pale precipitation is taken after centrifugation.
Preferably, step D) in Binding Buffer dosage and the dosage phase of Binding Buffer in step C) Deng.
Preferably, step E) described in albuminous degeneration liquid be concentration be 7.5~8.5M urea liquid;The albumen is multiple Property liquid be concentration be 1.8~2.2M urea liquid.
Preferably, step E) described in stirring condition utilize magnetic rotor realize.
Preferably, step E) described in mix be to be stirred 3~5h under the conditions of 2~6 DEG C.
Preferably, step E) continue to execute following operation after the completion: TEM1 negative cells and TEM1 positive cell are taken, are adopted The binding ability of the protein product obtained by flow cytomery and TEM1 negative cells, TEM1 positive cell;Using MTT colorimetric Killing ability of the method detection gained protein product to TEM1 negative cells, TEM1 positive cell.
Preferably, the TEM1 positive cell is prepared by the following method:
M) it obtains TEM1 segment: plasmid pCMV6-XL4-TEM1 being taken to obtain TEM1 segment using glue recycling after double digestion;
N) it constructs- 3Zf (-)-TEM1 recombinant plasmid: the TEM1 segment obtained in step m) is connected by digestion The method connect, is connected toIn -3Zf (-) plasmid to get arrive recombinant plasmid-3Zf(-)-TEM1;
O) it constructs- 3Zf (-)-TEM1-Top10 recombinant bacterial strain: step n) is resulting-3Zf (-)-TEM1 recombinant plasmid is transferred in E.coli Top10, obtains recombinant bacterial strain-3Zf(-)-TEM1-Top10;
P) it constructs pIRES-TEM1-EGFP recombinant plasmid: obtaining from the recombinant bacterial strain obtained in step o) containing TEM1 's- 3Zf (-)-TEM1 recombinant plasmid, by digestion connect method, be connected in pIRES-EGFP plasmid to get To recombinant plasmid pIRES-TEM1-EGFP;
Q) it constructs pIRES-TEM1-EGFP-Top10 recombinant bacterial strain: recombinant plasmid pIRES-TEM1-EGFP is transferred to In E.coli Top10, recombinant bacterial strain pIRES-TEM1-EGFP-Top10 is obtained;
R) construct TEM1 positive MS1 cell: extract from the step q) pIRES-TEM1-EGFP recombinant plasmid electricity rotate into TEM1 negative cells MS1 screens to obtain TEM1 positive cell line by G418.
In above technical scheme, the T18 is the single-chain antibody of specific recognition TEM1 a kind of, the title of the antibody (i.e. T18) belongs to from wound vocabulary.The T18-Aif expressing gene refers to the recombinant single chain antibody T18 for being integrated with Aif expressing gene Expressing gene.As a kind of from wound vocabulary, the technical characteristic of T18-Aif expressing gene is by sequence such as SEQ ID No.2 institute The DNA characterization shown;In the case where knowing particular sequence, which can pass through the synthesis side DNA conventional in the art Method obtains.
The present invention provides a kind of bacterial strain of recombinant single chain antibody for expressing AIF and being integrated with AIF and the bacterial strains Using.Characteristic of the technical solution using single-chain antibody T18 and tumor endothelial cell marker molecule TEM1 specific binding, building AIF-T18 albumen composition, to realize that apoptosis inducing factor AIF to the target administration of tumour cell, promotes it to tumour The apoptosis-induced effect of cell.The present invention is integrated with AIF-T18 expressing gene by vector construction of pET302 plasmid first Recombinant plasmid is then that host imports recombinant plasmid wherein with prokaryotic expression system E.coli BL21, has obtained having and stablize The recombinant bacterial strain of ability to express.On this basis, the present invention devises efficient protein expression side around the characteristic of the recombinant bacterium Method, and for suitable denaturation, renaturation, purification condition is had matched with protein expressioning product existing for inclusion bodies, thus real Effective preparation of AIF-T18 is showed.
At the same time, for investigate above prepared protein product and TEM1 positive cell specific binding capacity and its To the fragmentation effect of tumour cell, the present invention is further provided with the compliance test result step for above-mentioned albumen.
The present invention successfully constructs a kind of recombinant plasmid for being integrated with Aif-T18 expressing fusion protein gene, and is with it Basis has obtained one plant and has stablized expression Aif-T18 fusion protein recombination E.coli bacterial strain.The present invention successfully constructs one plant simultaneously Stable TEM1 positive cell line is laid a good foundation for the verifying of above-mentioned albumen effect.Show the fusion protein pair after verified TEM1 positive cell has the lethal effect of specificity, meets the new concept of ADC medicament research and development, helps to realize specific killing The good result of tumour achievees the purpose that treat tumor disease.
Detailed description of the invention
Fig. 1 is the structural schematic diagram of pET302-Aif-T18 of the present invention Yu pET302-Aif recombinant plasmid;
Fig. 2 is Aif-T18 and Aif protein purification and Western result figure in the specific embodiment of the invention;
Fig. 3 be in the specific embodiment of the invention TEM1 in MS1 cell inner expression fluorescence results figure;
Fig. 4 is TEM1 albumen Western result figure in MS1 and MS1-TEM1 in the specific embodiment of the invention;
Fig. 5 is Aif-T18 fusion protein in the specific embodiment of the invention, the binding ability detection of Aif albumen and cell Result figure
Fig. 6 is Aif-T18 fusion protein in the specific embodiment of the invention, and the lethality of Aif protein on cells detects knot Fruit figure.
Specific embodiment
Below by specific embodiments of the present invention will be described in detail.In order to avoid excessive unnecessary details, In It will not be described in detail in following embodiment to belonging to well known structure or function.In addition to being defined, institute in following embodiment Technical and scientific term has the identical meanings being commonly understood by with those skilled in the art of the invention.
Test reagent consumptive material used in following embodiment is unless otherwise specified conventional biochemical reagent;The experiment Method is unless otherwise specified conventional method;Quantitative test in following embodiment is respectively provided with three repeated experiments, as a result It is averaged;% in following embodiment is unless otherwise instructed mass percentage.
Embodiment 1
The building of 1.1 recombinant expression systems and the expression of Aif, Aif-T18 albumen
(1) chemical synthesis contains the pET302 (SEQ of Aif-T18 (SEQ ID No.2) segment and Aif (SEQ ID No.1) ID No.4) plasmid (as shown in Figure 1), it is transferred in E.coli BL21, picking pET302-Aif-T18 and pET302-Aif Dan Ke Grand access 10mL LB culture medium (containing Amp), 37 DEG C, 200rpm shakes bacterium overnight;
(2) bacterium solution obtained in step (1) is added in new expansion culture medium (200mL LB) in 5% ratio, To bacterium solution OD value between 0.6-0.8, (IPTG concentration is 1M, by 1/1000 addition, bacterium solution for addition inducer IPTG (1/1000) In the final concentration of 1mM of IPTG), 37 DEG C, 200rpm, 4h;
(3) the Binding Buffer of 20-25mL is added, ultrasonication beats 5s, stop 8s, 95 times, power 200W, 2 Circulation.It is become less viscous to bacterium solution thick, stops broken when more limpid, 10000rpm is centrifuged 10min, and supernatant is transferred to newly 50mL centrifuge tube, 4 DEG C preservation.
(4) it is precipitated, the substance of white is washed off, after centrifugation with more washings of Triton X-100/EDTA Solution Pale precipitation is inclusion body, and with the isometric Binding Buffer of thallus is resuspended by inclusion body resuspension, 4 DEG C of ice Case saves.
(5) washed inclusion body Aif-T18 and Aif are dissolved into denaturing liquid (urea of 8M), make its final concentration of 30- 50mg/ml, room temperature rotates 4h on gyroscope, the inclusion body 13000rpm centrifugation 30min of dissolution is removed impurity later, then It is slowly added into renaturation solution (urea of 2M) (1:100), is added portionwise, mixed every time, rotor rotation is added, by renaturation Liquid is concentrated into suitable volumes after being placed in 4 DEG C of renaturation 36-48h, 8000rpm centrifugations, by 1;4 ratio and His beads (1mL) is tied It closes, rotation mixes 4h on 4 DEG C of gyroscopes, is eluted albumen from beads with the imidazoles of 500mM, by the egg after elution It is white to be dialysed with PBS, it is final to obtain Aif-T18 and AIF albumen.As shown in Figure 2.
The building of 1.2TEM1 positive cell line
(1) plasmid pCMV6-XL4 withUsing after EcoRI-HF and XbaI double digestion, glue recycling obtains -3Zf (-) TEM1 segment is connected to by sequence TEM1 segment as shown in SEQ ID No.3 using T4 ligase-3Zf(-) In (SEQ ID No.5), is screened and obtained by amicillin resistance- 3Zf (-)-TEM1 recombinant plasmid, will recombinate Plasmid is transferred in E.coli Top10, obtains recombinant bacterial strain;
(2) by acquisition in step (1)- 3Zf (-)-TEM1 recombinant plasmid and pIRES-EGFP are used After EcoRI-HF and PstI-HF double digestion, TEM1 is connected to pIRES-EGFP after purification, using T4 ligase by digestion products In (SEQ ID No.6), is screened by amicillin resistance and obtain pIRES-TEM1-EGFP recombinant plasmid;It, will after verified Recombinant plasmid pIRES-TEM1-EGFP is converted to E.coli top10, obtains recombinant bacterial strain.
(3) the pIRES-TEM1-EGFP recombinant plasmid obtained is mixed with MS1 cell culture fluid, total volume 500 μL;Using 0.2cm electricity revolving cup, condition setting is 200 Ω 25uF of 1.8KV, and electricity turns time 4.7ms, and acquisition contains pIRES- The MS1 cell of TEM1-EGFP recombinant plasmid, i.e. TEM1 positive cell;Final using the liquid medium-selection containing G418 simultaneously To stable TEM1 positive cell line.Such as Fig. 3 and Fig. 4.
The performance verification of albumen prepared by 1.3 Section 1
A kind of site specific recognition TEM1 kills the fusion protein Aif-T18 function verification method of tumour, with building On the basis of TEM1 positive cell line, Aif albumen and Aif-T18 albumen and TEM1 positive cell is respectively adopted and TEM1 is negative thin Born of the same parents MS1 is incubated for 1-3 hours jointly, uses the binding specificity of flow cytomery Aif albumen and Aif-T18 albumen later, The result shows that Aif albumen does not have the ability of specific binding TEM1 positive cell, and Aif-T18 can specifically bind TEM1 Positive cell.Such as Fig. 5.
A kind of site specific recognition TEM1 kills the fusion protein Aif-T18 function verification method of tumour, with building On the basis of TEM1 positive cell line, Aif albumen and Aif-T18 albumen processing TEM1 positive cell is respectively adopted and TEM1 is negative Use MTT colorimetric determination Aif albumen and Aif-T18 albumen to the killing energy of the specificity of TEM1 positive cell after cell MS1 Power, the results showed that, Aif-T18 energy specific killing TEM1 positive cell, targeting ability is significantly stronger than Aif albumen.Such as Fig. 6.
Embodiment 2
A kind of bacterial strain of the recombinant single chain antibody for expressing AIF and being integrated with AIF, which prepared by following methods :
1) take sequence Aif expressing gene as shown in SEQ ID No.1, sequence as shown in SEQ ID No.2 respectively Aif-T18 expressing gene is connect by digestion mode with pET302 plasmid respectively, respectively obtain recombinant plasmid pET302-Aif, pET302-Aif-T18;
2) step 1) resulting recombinant plasmid pET302-Aif, pET302-Aif-T18 are taken respectively, are transferred to E.coli respectively In BL21, respectively obtain recombinant bacterium pET302-Aif-B21 and pET302-Aif-T18-B21, it is as described for express AIF and It is integrated with the bacterial strain of the recombinant single chain antibody of AIF.
A method of AIF is prepared using above-mentioned bacterial strains and is integrated with the recombinant single chain antibody of AIF, comprising the following steps:
A bacterial strain described in claim 1) is taken to access in LB culture medium with ampicillin, 35 DEG C of shake cultures are stayed overnight;
B step A) is taken) obtained bacterium solution is cultivated, it is seeded in fresh LB culture medium, is trained with the inoculum concentration of 3% (v/v) Supporting to bacterium solution OD value is 0.6, inducer IPTG to final concentration 0.8mM is added, then in 35 DEG C of shake culture 3h;
C it) is separated by solid-liquid separation and takes precipitating, thallus is resuspended in the Binding Buffer that 20mL is added, and ultrasonication, then solid-liquid divides It is precipitated from taking;
D inclusion body) is collected from the step C) sediment, inclusion body is resuspended in the Binding Buffer that 20mL is added;
E step D) is taken) resulting solubilization of inclusion bodies is in albuminous degeneration liquid, until wherein inclusion body protein is final concentration of 30mg/ml, room temperature shake 3h, are then centrifuged 25min with the revolving speed of 12000rpm, take supernatant, it is added with the volume ratio of 1:80 Enter into protein renaturation liquid, keep 36h under agitation, in 2 DEG C of environment, presses the volume ratio of 1:3 after concentration with His beads It mixes, then elutes albumen using the imidazole solution that concentration is 450mM, recycle PBS solution dialysis.
On the basis of above technical scheme, meet the following conditions:
Step C) described in ultrasonication condition are as follows: every ultrasonic treatment 5s stops 8s, so repeats 95 times, power is 200W, 2 circulations.
Step C) in second condition being separated by solid-liquid separation are as follows: the revolving speed of 8000rpm is centrifuged 8min.
Step D) described in collect inclusion body, be first to wash precipitating with Triton X-100/EDTA Solution, centrifugation After take the pale precipitation to be inclusion body.
Step D) in Binding Buffer dosage it is equal with the dosage of Binding Buffer in step C).
Step E) described in albuminous degeneration liquid be concentration be 7.5M urea liquid;The protein renaturation liquid is that concentration is The urea liquid of 1.8M.
Step E) described in mix be to be stirred 3h under the conditions of 2 DEG C.
Step E) continue to execute following operation after the completion: TEM1 negative cells and TEM1 positive cell are taken, it is thin using streaming The binding ability of born of the same parents' instrument detection gained protein product and TEM1 negative cells, TEM1 positive cell;Using MTT colorimetric determination institute Protein product is obtained to the killing ability of TEM1 negative cells, TEM1 positive cell.
The TEM1 positive cell is prepared by the following method:
M) it obtains TEM1 segment: plasmid pCMV6-XL4-TEM1 being taken to obtain TEM1 segment using glue recycling after double digestion;
N) it constructs- 3Zf (-)-TEM1 recombinant plasmid: the TEM1 segment obtained in step m) is connected by digestion The method connect, is connected toIn -3Zf (-) plasmid to get arrive recombinant plasmid-3Zf(-)-TEM1;
O) it constructs- 3Zf (-)-TEM1-Top10 recombinant bacterial strain: step n) is resulting-3Zf (-)-TEM1 recombinant plasmid is transferred in E.coli Top10, obtains recombinant bacterial strain-3Zf(-)-TEM1-Top10;
P) it constructs pIRES-TEM1-EGFP recombinant plasmid: obtaining from the recombinant bacterial strain obtained in step o) containing TEM1 's- 3Zf (-)-TEM1 recombinant plasmid, by digestion connect method, be connected in pIRES-EGFP plasmid to get To recombinant plasmid pIRES-TEM1-EGFP;
Q) it constructs pIRES-TEM1-EGFP-Top10 recombinant bacterial strain: recombinant plasmid pIRES-TEM1-EGFP is transferred to In E.coli Top10, recombinant bacterial strain pIRES-TEM1-EGFP-Top10 is obtained;
R) construct TEM1 positive MS1 cell: extract from the step q) pIRES-TEM1-EGFP recombinant plasmid electricity rotate into TEM1 negative cells MS1 screens to obtain TEM1 positive cell line by G418.
Embodiment 3
A kind of bacterial strain of the recombinant single chain antibody for expressing AIF and being integrated with AIF, which prepared by following methods :
1) take sequence Aif expressing gene as shown in SEQ ID No.1, sequence as shown in SEQ ID No.2 respectively Aif-T18 expressing gene is connect by digestion mode with pET302 plasmid respectively, respectively obtain recombinant plasmid pET302-Aif, pET302-Aif-T18;
2) step 1) resulting recombinant plasmid pET302-Aif, pET302-Aif-T18 are taken respectively, are transferred to E.coli respectively In BL21, respectively obtain recombinant bacterium pET302-Aif-B21 and pET302-Aif-T18-B21, it is as described for express AIF and It is integrated with the bacterial strain of the recombinant single chain antibody of AIF.
A method of AIF is prepared using above-mentioned bacterial strains and is integrated with the recombinant single chain antibody of AIF, comprising the following steps:
A bacterial strain described in claim 1) is taken to access in LB culture medium with ampicillin, 39 DEG C of shake cultures are stayed overnight;
B step A) is taken) obtained bacterium solution is cultivated, it is seeded in fresh LB culture medium, is trained with the inoculum concentration of 7% (v/v) Supporting to bacterium solution OD value is 0.8, inducer IPTG to final concentration 1.2mM is added, then in 39 DEG C of shake culture 5h;
C it) is separated by solid-liquid separation and takes precipitating, thallus is resuspended in the Binding Buffer that 25mL is added, and ultrasonication, then solid-liquid divides It is precipitated from taking;
D inclusion body) is collected from the step C) sediment, inclusion body is resuspended in the Binding Buffer that 25mL is added;
E step D) is taken) resulting solubilization of inclusion bodies is in albuminous degeneration liquid, until wherein inclusion body protein is final concentration of 50mg/ml, room temperature shake 5h, are then centrifuged 35min with the revolving speed of 14000rpm, take supernatant, it is added with the volume ratio of 1:120 Enter into protein renaturation liquid, keep 48h under agitation, in 6 DEG C of environment, presses the volume ratio of 1:5 after concentration with His beads It mixes, then elutes albumen using the imidazole solution that concentration is 550mM, recycle PBS solution dialysis.
On the basis of above technical scheme, meet the following conditions:
Step C) in second condition being separated by solid-liquid separation are as follows: the revolving speed of 12000rpm is centrifuged 12min.
Step E) described in albuminous degeneration liquid be concentration be 8.5M urea liquid;The protein renaturation liquid is that concentration is The urea liquid of 2.2M.
Step E) described in mix be to be stirred 5h under the conditions of 6 DEG C.
Step E) continue to execute following operation after the completion: TEM1 negative cells and TEM1 positive cell are taken, it is thin using streaming The binding ability of born of the same parents' instrument detection gained protein product and TEM1 negative cells, TEM1 positive cell;Using MTT colorimetric determination institute Protein product is obtained to the killing ability of TEM1 negative cells, TEM1 positive cell.
Embodiment 4
A kind of bacterial strain of the recombinant single chain antibody for expressing AIF and being integrated with AIF, which prepared by following methods :
1) take sequence Aif expressing gene as shown in SEQ ID No.1, sequence as shown in SEQ ID No.2 respectively Aif-T18 expressing gene is connect by digestion mode with pET302 plasmid respectively, respectively obtain recombinant plasmid pET302-Aif, pET302-Aif-T18;
2) step 1) resulting recombinant plasmid pET302-Aif, pET302-Aif-T18 are taken respectively, are transferred to E.coli respectively In BL21, respectively obtain recombinant bacterium pET302-Aif-B21 and pET302-Aif-T18-B21, it is as described for express AIF and It is integrated with the bacterial strain of the recombinant single chain antibody of AIF.
A method of AIF is prepared using above-mentioned bacterial strains and is integrated with the recombinant single chain antibody of AIF, comprising the following steps:
A bacterial strain described in claim 1) is taken to access in LB culture medium with ampicillin, 37 DEG C of shake cultures are stayed overnight;
B step A) is taken) obtained bacterium solution is cultivated, it is seeded in fresh LB culture medium, is trained with the inoculum concentration of 5% (v/v) Supporting to bacterium solution OD value is 0.7, inducer IPTG to final concentration 1mM is added, then in 37 DEG C of shake culture 4h;
C it) is separated by solid-liquid separation and takes precipitating, thallus is resuspended in the Binding Buffer that 22mL is added, and ultrasonication, then solid-liquid divides It is precipitated from taking;
D inclusion body) is collected from the step C) sediment, inclusion body is resuspended in the Binding Buffer that 22mL is added;
E step D) is taken) resulting solubilization of inclusion bodies is in albuminous degeneration liquid, until wherein inclusion body protein is final concentration of 40mg/ml, room temperature shake 4h, are then centrifuged 30min with the revolving speed of 13000rpm, take supernatant, it is added with the volume ratio of 1:100 Enter into protein renaturation liquid, keep 42h under agitation, in 4 DEG C of environment, presses the volume ratio of 1:4 after concentration with His beads It mixes, then elutes albumen using the imidazole solution that concentration is 500mM, recycle PBS solution dialysis.
The embodiments of the present invention have been described in detail above, but content is only the preferred embodiment of the present invention, It is not intended to limit the invention.All any modifications, equivalent replacements, and improvements etc. done in application range of the invention, should all It is included within protection scope of the present invention.
SEQUENCE LISTING
<110>University Of Nanchang
<120>for express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain application
<160> 6
<170> PatentIn version 3.3
<210> 1
<211> 1536
<212> DNA
<213>artificial sequence
<400> 1
ttagggctga caccagaaca gaaacagaaa aaggccgcgt tatctgcttc agaaggagag 60
gaagttcctc aagacaaggc gccaagtcat gttcctttcc tgctaattgg tggaggcaca 120
gctgcttttg ctgcagccag atccatccgg gctcgggatc ctggggccag ggtactgatt 180
gtatctgaag atcctgagct gccgtacatg cgacctcctc tttcaaaaga actgtggttt 240
tcagatgacc caaatgtcac aaagacactg cgattcaaac agtggaatgg aaaagagaga 300
agcatatatt tccagccacc ttctttctat gtctctgctc aggacctgcc tcatattgag 360
aatggtggtg tggctgtcct cactgggaag aaggtagtac agctggatgt gagagacaac 420
atggtgaaac ttaatgatgg ctctcaaata acctatgaaa agtgcttgat tgcaacagga 480
ggtactccaa gaagtctgtc tgccattgat agggctggag cagaggtgaa gagtagaaca 540
acgcttttca gaaagattgg agactttaga agcttggaga agatttcacg ggaagtcaaa 600
tcaattacga ttatcggtgg gggcttcctt ggtagcgaac tggcctgtgc tcttggcaga 660
aaggctcgag ccttgggcac agaagtgatt caactcttcc ccgagaaagg aaatatggga 720
aagatcctcc ccgaatacct cagcaactgg accatggaaa aagtcagacg agagggggtt 780
aaggtgatgc ccaatgctat tgtgcaatcc gttggagtca gcagtggcaa gttacttatc 840
aagctgaaag acggcaggaa ggtagaaact gaccacatag tggcagctgt gggcctggag 900
cccaatgttg agttggccaa gactggtggc ctggaaatag actcagattt tggtggcttc 960
cgggtaaatg cagagctaca agcacgctct aacatctggg tggcaggaga tgctgcatgc 1020
ttctacgata taaagttggg aaggaggcgg gtagagcacc atgatcacgc tgttgtgagt 1080
ggaagattgg ctggagaaaa tatgactgga gctgctaagc cgtactggca tcagtcaatg 1140
ttctggagtg atttgggccc cgatgttggc tatgaagcta ttggtcttgt ggacagtagt 1200
ttgcccacag ttggtgtttt tgcaaaagca actgcacaag acaaccccaa atctgccaca 1260
gagcagtcag gaactggtat ccgatcagag agtgagacag agtccgaggc ctcagaaatt 1320
actattcctc ccagcacccc ggcagttcca caggctcccg tccaggggga ggactacggc 1380
aaaggtgtca tcttctacct cagggacaaa gtggtcgtgg ggattgtgct atggaacatc 1440
tttaaccgaa tgccaatagc aaggaagatc attaaggacg gtgagcagca tgaagatctc 1500
aatgaagtag ccaaactatt caacattcat gaagac 1536
<210> 2
<211> 2376
<212> DNA
<213>artificial sequence
<400> 2
ttagggctga caccagaaca gaaacagaaa aaggccgcgt tatctgcttc agaaggagag 60
gaagttcctc aagacaaggc gccaagtcat gttcctttcc tgctaattgg tggaggcaca 120
gctgcttttg ctgcagccag atccatccgg gctcgggatc ctggggccag ggtactgatt 180
gtatctgaag atcctgagct gccgtacatg cgacctcctc tttcaaaaga actgtggttt 240
tcagatgacc caaatgtcac aaagacactg cgattcaaac agtggaatgg aaaagagaga 300
agcatatatt tccagccacc ttctttctat gtctctgctc aggacctgcc tcatattgag 360
aatggtggtg tggctgtcct cactgggaag aaggtagtac agctggatgt gagagacaac 420
atggtgaaac ttaatgatgg ctctcaaata acctatgaaa agtgcttgat tgcaacagga 480
ggtactccaa gaagtctgtc tgccattgat agggctggag cagaggtgaa gagtagaaca 540
acgcttttca gaaagattgg agactttaga agcttggaga agatttcacg ggaagtcaaa 600
tcaattacga ttatcggtgg gggcttcctt ggtagcgaac tggcctgtgc tcttggcaga 660
aaggctcgag ccttgggcac agaagtgatt caactcttcc ccgagaaagg aaatatggga 720
aagatcctcc ccgaatacct cagcaactgg accatggaaa aagtcagacg agagggggtt 780
aaggtgatgc ccaatgctat tgtgcaatcc gttggagtca gcagtggcaa gttacttatc 840
aagctgaaag acggcaggaa ggtagaaact gaccacatag tggcagctgt gggcctggag 900
cccaatgttg agttggccaa gactggtggc ctggaaatag actcagattt tggtggcttc 960
cgggtaaatg cagagctaca agcacgctct aacatctggg tggcaggaga tgctgcatgc 1020
ttctacgata taaagttggg aaggaggcgg gtagagcacc atgatcacgc tgttgtgagt 1080
ggaagattgg ctggagaaaa tatgactgga gctgctaagc cgtactggca tcagtcaatg 1140
ttctggagtg atttgggccc cgatgttggc tatgaagcta ttggtcttgt ggacagtagt 1200
ttgcccacag ttggtgtttt tgcaaaagca actgcacaag acaaccccaa atctgccaca 1260
gagcagtcag gaactggtat ccgatcagag agtgagacag agtccgaggc ctcagaaatt 1320
actattcctc ccagcacccc ggcagttcca caggctcccg tccaggggga ggactacggc 1380
aaaggtgtca tcttctacct cagggacaaa gtggtcgtgg ggattgtgct atggaacatc 1440
tttaaccgaa tgccaatagc aaggaagatc attaaggacg gtgagcagca tgaagatctc 1500
aatgaagtag ccaaactatt caacattcat gaagacgaat tcgcgggtaa tcgtgtgcgt 1560
cgctctgttg gtcttaaggg tggtggaggt ggttctggtg gtggaggttc tggtggtggt 1620
ggatctggcc agcttgtgct gactcagcca ccttccctct ctgcatctcc tggagcatca 1680
gccagtctca cctgcacctt acgcagtgac atcaatgttg gttcctacag gatatcctgg 1740
taccagcaga agccagggag tcctccccag tatctcctga gctacaaatc agactcagat 1800
aagcagaagg gctctggagt ccccagccgc ttctctggat ccaaagatgc ttcggccaat 1860
gcagggattt tactcatctc tgggctccag tctgaggatg aggctgacta ttattgtatg 1920
atttggcaca acagcgctgg ggtgttcggc gggggcacca agctgaccgt cctaggcggt 1980
ggttcctcta gatcttcctc ctctggtggc ggtggctcgg gcggtggtgg gcaggtgcag 2040
ctgcaggagt cgggaggaac cttggtacag cctggggggt ccctgagact ctcttgtgaa 2100
gcctctggat tcacctttag caactatgcc atgggctggg tccgccagac tccaggaaag 2160
gggctggagt ggctgtcggc tattcgtaaa agtggcacta ccacatacta cgcggactcc 2220
gtgaagggcc ggttcatcat ctccagagac aattccaaga acaccctgta tctgcaaatg 2280
aataggctga gagtcggcga cacggccact tattactgtg cgactcaccc catcgcgggc 2340
tactggggcc agggaagcct ggtcactgtc tcctcc 2376
<210> 3
<211> 2576
<212> DNA
<213>artificial sequence
<400> 3
agtccggggg catcgcgatg ctgctgcgcc tgttgctggc ctgggcggcc gcagggccca 60
cactgggcca ggacccctgg gctgctgagc cccgtgccgc ctgcggcccc agcagctgct 120
acgctctctt cccacggcgc cgcaccttcc tggaggcctg gcgggcctgc cgcgagctgg 180
ggggcgacct ggccactcct cggacccccg aggaggccca gcgtgtggac agcctggtgg 240
gtgcgggccc agccagccgg ctgctgtgga tcgggctgca gcggcaggcc cggcaatgcc 300
agctgcagcg cccactgcgc ggcttcacgt ggaccacagg ggaccaggac acggctttca 360
ccaactgggc ccagccagcc tctggaggcc cctgcccggc ccagcgctgt gtggccctgg 420
aggcaagtgg cgagcaccgc tggctggagg gctcgtgcac gctggctgtc gacggctacc 480
tgtgccagtt tggcttcgag ggcgcctgcc cggcgctgca agatgaggcg ggccaggccg 540
gcccagccgt gtataccacg cccttccacc tggtctccac agagtttgag tggctgccct 600
tcggctctgt ggccgctgtg cagtgccagg ctggcagggg agcctctctg ctctgcgtga 660
agcagcctga gggaggtgtg ggctggtcac gggctgggcc cctgtgcctg gggactggct 720
gcagccctga caacgggggc tgcgaacacg aatgtgtgga ggaggtggat ggtcacgtgt 780
cctgccgctg cactgagggc ttccggctgg cagcagacgg gcgcagttgc gaggacccct 840
gtgcccaggc tccgtgcgag cagcagtgtg agcccggtgg gccacaaggc tacagctgcc 900
actgtcgcct gggtttccgg ccagcggagg atgatccgca ccgctgtgtg gacacagatg 960
agtgccagat tgccggtgtg tgccagcaga tgtgtgtcaa ctacgttggt ggcttcgagt 1020
gttattgtag cgagggacat gagctggagg ctgatggcat cagctgcagc cctgcagggg 1080
ccatgggtgc ccaggcttcc caggacctcg gagatgagtt gctggatgac ggggaggatg 1140
aggaagatga agacgaggcc tggaaggcct tcaacggtgg ctggacggag atgcctggga 1200
tcctgtggat ggagcctacg cagccgcctg actttgccct ggcctataga ccgagcttcc 1260
cagaggacag agagccacag ataccctacc cggagcccac ctggccaccc ccgctcagtg 1320
cccccagggt cccctaccac tcctcagtgc tctccgtcac ccggcctgtg gtggtctctg 1380
ccacgcatcc cacactgcct tctgcccacc agcctcctgt gatccctgcc acacacccag 1440
ctttgtcccg tgaccaccag atccccgtga tcgcagccaa ctatccagat ctgccttctg 1500
cctaccaacc cggtattctc tctgtctctc attcagcaca gcctcctgcc caccagcccc 1560
ctatgatctc aaccaaatat ccggagctct tccctgccca ccagtccccc atgtttccag 1620
acacccgggt cgctggcacc cagaccacca ctcatttgcc tggaatccca cctaaccatg 1680
cccctctggt caccaccctc ggtgcccagc taccccctca agccccagat gcccttgtcc 1740
tcagaaccca ggccacccag cttcccatta tcccaactgc ccagccctct ctgaccacca 1800
cctccaggtc ccctgtgtct cctgcccatc aaatctctgt gcctgctgcc acccagcccg 1860
cagccctccc caccctcctg ccctctcaga gccccactaa ccagacctca cccatcagcc 1920
ctacacatcc ccattccaaa gccccccaaa tcccaaggga agatggcccc agtcccaagt 1980
tggccctgtg gctgccctca ccagctccca cagcagcccc aacagccctg ggggaggctg 2040
gtcttgccga gcacagccag agggatgacc ggtggctgct ggtggcactc ctggtgccaa 2100
cgtgtgtctt tttggtggtc ctgcttgcac tgggcatcgt gtactgcacc cgctgtggcc 2160
cccatgcacc caacaagcgc atcactgact gctatcgctg ggtcatccat gctgggagca 2220
agagcccaac agaacccatg ccccccaggg gcagcctcac aggggtgcag acctgcagaa 2280
ccagcgtgtg atggggtgca gacccccctc atggagtatg gggcgctgga cacatggccg 2340
gggctgcacc agggacccat gggggctgcc cagctggaca gatggcttcc tgctccccag 2400
gcccagccag ggtcctctct caaccactag acttggctct caggaactct gcttcctggc 2460
ccagcgctcg tgaccaagga tacaccaaag cccttaagac ctcagggggc gggtgctggg 2520
gtcttctcca ataaatgggg tgtcaacctt acccaaggaa aaaaaaaaaa aaaaaa 2576
<210> 4
<211> 5712
<212> DNA
<213>artificial sequence
<400> 4
gatctcgatc ccgcgaaatt aatacgactc actatagggg aattgtgagc ggataacaat 60
tcccctctag aaataatttt gtttaaactt taagaaggag atatacatat gcatcatcat 120
catcatcacg tgaattcgct cgagatcgat gatattcgag cctaggtata atcggatccg 180
gctgctaaca aagcccgaaa ggaagctgag ttggctgctg ccaccgctga gcaataacta 240
gcataacccc ttggggcctc taaacgggtc ttgaggggtt ttttgctgaa aggaggaact 300
atatccggat atcccgcaag aggcccggca gtaccggcat aaccaagcct atgcctacag 360
catccagggt gacggtgccg aggatgacga tgagcgcatt gttagatttc atacacggtg 420
cctgactgcg ttagcaattt aactgtgata aactaccgca ttaaagctag cttatcgatg 480
ataagctgtc aaacatgaga attaattctt gaagacgaaa gggcctcgtg atacgcctat 540
ttttataggt taatgtcatg ataataatgg tttcttagac gtcaggtggc acttttcggg 600
gaaatgtgcg cggaacccct atttgtttat ttttctaaat acattcaaat atgtatccgc 660
tcatgagaca ataaccctga taaatgcttc aataatattg aaaaaggaag agtatgagta 720
ttcaacattt ccgtgtcgcc cttattccct tttttgcggc attttgcctt cctgtttttg 780
ctcacccaga aacgctggtg aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg 840
gttacatcga actggatctc aacagcggta agatccttga gagttttcgc cccgaagaac 900
gttttccaat gatgagcact tttaaagttc tgctatgtgg cgcggtatta tcccgtgttg 960
acgccgggca agagcaactc ggtcgccgca tacactattc tcagaatgac ttggttgagt 1020
actcaccagt cacagaaaag catcttacgg atggcatgac agtaagagaa ttatgcagtg 1080
ctgccataac catgagtgat aacactgcgg ccaacttact tctgacaacg atcggaggac 1140
cgaaggagct aaccgctttt ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt 1200
gggaaccgga gctgaatgaa gccataccaa acgacgagcg tgacaccacg atgcctgcag 1260
caatggcaac aacgttgcgc aaactattaa ctggcgaact acttactcta gcttcccggc 1320
aacaattaat agactggatg gaggcggata aagttgcagg accacttctg cgctcggccc 1380
ttccggctgg ctggtttatt gctgataaat ctggagccgg tgagcgtggg tctcgcggta 1440
tcattgcagc actggggcca gatggtaagc cctcccgtat cgtagttatc tacacgacgg 1500
ggagtcaggc aactatggat gaacgaaata gacagatcgc tgagataggt gcctcactga 1560
ttaagcattg gtaactgtca gaccaagttt actcatatat actttagatt gatttaaaac 1620
ttcattttta atttaaaagg atctaggtga agatcctttt tgataatctc atgaccaaaa 1680
tcccttaacg tgagttttcg ttccactgag cgtcagaccc cgtagaaaag atcaaaggat 1740
cttcttgaga tccttttttt ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc 1800
taccagcggt ggtttgtttg ccggatcaag agctaccaac tctttttccg aaggtaactg 1860
gcttcagcag agcgcagata ccaaatactg tccttctagt gtagccgtag ttaggccacc 1920
acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaatcctg ttaccagtgg 1980
ctgctgccag tggcgataag tcgtgtctta ccgggttgga ctcaagacga tagttaccgg 2040
ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac acagcccagc ttggagcgaa 2100
cgacctacac cgaactgaga tacctacagc gtgagctatg agaaagcgcc acgcttcccg 2160
aagggagaaa ggcggacagg tatccggtaa gcggcagggt cggaacagga gagcgcacga 2220
gggagcttcc agggggaaac gcctggtatc tttatagtcc tgtcgggttt cgccacctct 2280
gacttgagcg tcgatttttg tgatgctcgt caggggggcg gagcctatgg aaaaacgcca 2340
gcaacgcggc ctttttacgg ttcctggcct tttgctggcc ttttgctcac atgttctttc 2400
ctgcgttatc ccctgattct gtggataacc gtattaccgc ctttgagtga gctgataccg 2460
ctcgccgcag ccgaacgacc gagcgcagcg agtcagtgag cgaggaagcg gaagagcgcc 2520
tgatgcggta ttttctcctt acgcatctgt gcggtatttc acaccgcaat ggtgcactct 2580
cagtacaatc tgctctgatg ccgcatagtt aagccagtat acactccgct atcgctacgt 2640
gactgggtca tggctgcgcc ccgacacccg ccaacacccg ctgacgcgcc ctgacgggct 2700
tgtctgctcc cggcatccgc ttacagacaa gctgtgaccg tctccgggag ctgcatgtgt 2760
cagaggtttt caccgtcatc accgaaacgc gcgaggcagc tgcggtaaag ctcatcagcg 2820
tggtcgtgaa gcgattcaca gatgtctgcc tgttcatccg cgtccagctc gttgagtttc 2880
tccagaagcg ttaatgtctg gcttctgata aagcgggcca tgttaagggc ggttttttcc 2940
tgtttggtca ctgatgcctc cgtgtaaggg ggatttctgt tcatgggggt aatgataccg 3000
atgaaacgag agaggatgct cacgatacgg gttactgatg atgaacatgc ccggttactg 3060
gaacgttgtg agggtaaaca actggcggta tggatgcggc gggaccagag aaaaatcact 3120
cagggtcaat gccagcgctt cgttaataca gatgtaggtg ttccacaggg tagccagcag 3180
catcctgcga tgcagatccg gaacataatg gtgcagggcg ctgacttccg cgtttccaga 3240
ctttacgaaa cacggaaacc gaagaccatt catgttgttg ctcaggtcgc agacgttttg 3300
cagcagcagt cgcttcacgt tcgctcgcgt atcggtgatt cattctgcta accagtaagg 3360
caaccccgcc agcctagccg ggtcctcaac gacaggagca cgatcatgcg cacccgtggc 3420
caggacccaa cgctgcccga gatgcgccgc gtgcggctgc tggagatggc ggacgcgatg 3480
gatatgttct gccaagggtt ggtttgcgca ttcacagttc tccgcaagaa ttgattggct 3540
ccaattcttg gagtggtgaa tccgttagcg aggtgccgcc ggcttccatt caggtcgagg 3600
tggcccggct ccatgcaccg cgacgcaacg cggggaggca gacaaggtat agggcggcgc 3660
ctacaatcca tgccaacccg ttccatgtgc tcgccgaggc ggcataaatc gccgtgacga 3720
tcagcggtcc aatgatcgaa gttaggctgg taagagccgc gagcgatcct tgaagctgtc 3780
cctgatggtc gtcatctacc tgcctggaca gcatggcctg caacgcgggc atcccgatgc 3840
cgccggaagc gagaagaatc ataatgggga aggccatcca gcctcgcgtc gcgaacgcca 3900
gcaagacgta gcccagcgcg tcggccgcca tgccggcgat aatggcctgc ttctcgccga 3960
aacgtttggt ggcgggacca gtgacgaagg cttgagcgag ggcgtgcaag attccgaata 4020
ccgcaagcga caggccgatc atcgtcgcgc tccagcgaaa gcggtcctcg ccgaaaatga 4080
cccagagcgc tgccggcacc tgtcctacga gttgcatgat aaagaagaca gtcataagtg 4140
cggcgacgat agtcatgccc cgcgcccacc ggaaggagct gactgggttg aaggctctca 4200
agggcatcgg tcgagatccc ggtgcctaat gagtgagcta acttacatta attgcgttgc 4260
gctcactgcc cgctttccag tcgggaaacc tgtcgtgcca gctgcattaa tgaatcggcc 4320
aacgcgcggg gagaggcggt ttgcgtattg ggcgccaggg tggtttttct tttcaccagt 4380
gagacgggca acagctgatt gcccttcacc gcctggccct gagagagttg cagcaagcgg 4440
tccacgctgg tttgccccag caggcgaaaa tcctgtttga tggtggttaa cggcgggata 4500
taacatgagc tgtcttcggt atcgtcgtat cccactaccg agatatccgc accaacgcgc 4560
agcccggact cggtaatggc gcgcattgcg cccagcgcca tctgatcgtt ggcaaccagc 4620
atcgcagtgg gaacgatgcc ctcattcagc atttgcatgg tttgttgaaa accggacatg 4680
gcactccagt cgccttcccg ttccgctatc ggctgaattt gattgcgagt gagatattta 4740
tgccagccag ccagacgcag acgcgccgag acagaactta atgggcccgc taacagcgcg 4800
atttgctggt gacccaatgc gaccagatgc tccacgccca gtcgcgtacc gtcttcatgg 4860
gagaaaataa tactgttgat gggtgtctgg tcagagacat caagaaataa cgccggaaca 4920
ttagtgcagg cagcttccac agcaatggca tcctggtcat ccagcggata gttaatgatc 4980
agcccactga cgcgttgcgc gagaagattg tgcaccgccg ctttacaggc ttcgacgccg 5040
cttcgttcta ccatcgacac caccacgctg gcacccagtt gatcggcgcg agatttaatc 5100
gccgcgacaa tttgcgacgg cgcgtgcagg gccagactgg aggtggcaac gccaatcagc 5160
aacgactgtt tgcccgccag ttgttgtgcc acgcggttgg gaatgtaatt cagctccgcc 5220
atcgccgctt ccactttttc ccgcgttttc gcagaaacgt ggctggcctg gttcaccacg 5280
cgggaaacgg tctgataaga gacaccggca tactctgcga catcgtataa cgttactggt 5340
ttcacattca ccaccctgaa ttgactctct tccgggcgct atcatgccat accgcgaaag 5400
gttttgcgcc attcgatggt gtccgggatc tcgacgctct cccttatgcg actcctgcat 5460
taggaagcag cccagtagta ggttgaggcc gttgagcacc gccgccgcaa ggaatggtgc 5520
atgcaaggag atggcgccca acagtccccc ggccacgggg cctgccacca tacccacgcc 5580
gaaacaagcg ctcatgagcc cgaagtggcg agcccgatct tccccatcgg tgatgtcggc 5640
gatataggcg ccagcaaccg cacctgtggc gccggtgatg ccggccacga tgcgtccggc 5700
gtagaggatc ga 5712
<210> 5
<211> 3197
<212> DNA
<213>artificial sequence
<400> 5
gggcgaattc gagctcggta cccggggatc ctctagagtc gacctgcagg catgcaagct 60
tgagtattct atagtgtcac ctaaatagct tggcgtaatc atggtcatag ctgtttcctg 120
tgtgaaattg ttatccgctc acaattccac acaacatacg agccggaagc ataaagtgta 180
aagcctgggg tgcctaatga gtgagctaac tcacattaat tgcgttgcgc tcactgcccg 240
ctttccagtc gggaaacctg tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga 300
gaggcggttt gcgtattggg cgctcttccg cttcctcgct cactgactcg ctgcgctcgg 360
tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag 420
aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc 480
gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg cccccctgac gagcatcaca 540
aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt 600
ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc 660
tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc tgtaggtatc 720
tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc 780
ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caacccggta agacacgact 840
tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggtat gtaggcggtg 900
ctacagagtt cttgaagtgg tggcctaact acggctacac tagaagaaca gtatttggta 960
tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca 1020
aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa 1080
aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaacg 1140
aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc 1200
ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg 1260
acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat 1320
ccatagttgc ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg 1380
gccccagtgc tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa 1440
taaaccagcc agccggaagg gccgagcgca gaagtggtcc tgcaacttta tccgcctcca 1500
tccagtctat taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc 1560
gcaacgttgt tgccattgct acaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt 1620
cattcagctc cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa 1680
aagcggttag ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat 1740
cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct 1800
tttctgtgac tggtgagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga 1860
gttgctcttg cccggcgtca atacgggata ataccgcgcc acatagcaga actttaaaag 1920
tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga 1980
gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca 2040
ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg 2100
cgacacggaa atgttgaata ctcatactct tcctttttca atattattga agcatttatc 2160
agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag 2220
gggttccgcg cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc attattatca 2280
tgacattaac ctataaaaat aggcgtatca cgaggccctt tcgtctcgcg cgtttcggtg 2340
atgacggtga aaacctctga cacatgcagc tcccggagac ggtcacagct tgtctgtaag 2400
cggatgccgg gagcagacaa gcccgtcagg gcgcgtcagc gggtgttggc gggtgtcggg 2460
gctggcttaa ctatgcggca tcagagcaga ttgtactgag agtgcaccat atgcggtgtg 2520
aaataccgca cagatgcgta aggagaaaat accgcatcag gacgcgccct gtagcggcgc 2580
attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc gctacacttg ccagcgccct 2640
agcgcccgct cctttcgctt tcttcccttc ctttctcgcc acgttcgccg gctttccccg 2700
tcaagctcta aatcgggggc tccctttagg gttccgattt agtgctttac ggcacctcga 2760
ccccaaaaaa cttgattagg gtgatggttc acgtagtggg ccatcgccct gatagacggt 2820
ttttcgccct ttgacgttgg agtccacgtt ctttaatagt ggactcttgt tccaaactgg 2880
aacaacactc aaccctatct cggtctattc ttttgattta taagggattt tgccgatttc 2940
ggcctattgg ttaaaaaatg agctgattta acaaaaattt aacgcgaatt ttaacaaaat 3000
attaacgctt acaatttcca ttcgccattc aggctgcgca actgttggga agggcgatcg 3060
gtgcgggcct cttcgctatt acgccagctg gcgaaagggg gatgtgctgc aaggcgatta 3120
agttgggtaa cgccagggtt ttcccagtca cgacgttgta aaacgacggc cagtgaattg 3180
taatacgact cactata 3197
<210> 6
<211> 5162
<212> DNA
<213>artificial sequence
<400> 6
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gcttggtacc 900
gagctcggat cgatatctgc ggccgcgtcg acggaattca gtggatccac tagtaacggc 960
cgccagtgtg ctggaattaa ttcgctgtct gcgagggcca gctgttgggg tgagtactcc 1020
ctctcaaaag cgggcatgac ttctgcgcta agattgtcag tttccaaaaa cgaggaggat 1080
ttgatattca cctggcccgc ggtgatgcct ttgagggtgg ccgcgtccat ctggtcagaa 1140
aagacaatct ttttgttgtc aagcttgagg tgtggcaggc ttgagatctg gccatacact 1200
tgagtgacaa tgacatccac tttgcctttc tctccacagg tgtccactcc caggtccaac 1260
tgcaggtcga gcatgcatct agggcggcca attccgcccc tctccctccc ccccccctaa 1320
cgttactggc cgaagccgct tggaataagg ccggtgtgcg tttgtctata tgtgattttc 1380
caccatattg ccgtcttttg gcaatgtgag ggcccggaaa cctggccctg tcttcttgac 1440
gagcattcct aggggtcttt cccctctcgc caaaggaatg caaggtctgt tgaatgtcgt 1500
gaaggaagca gttcctctgg aagcttcttg aagacaaaca acgtctgtag cgaccctttg 1560
caggcagcgg aaccccccac ctggcgacag gtgcctctgc ggccaaaagc cacgtgtata 1620
agatacacct gcaaaggcgg cacaacccca gtgccacgtt gtgagttgga tagttgtgga 1680
aagagtcaaa tggctctcct caagcgtatt caacaagggg ctgaaggatg cccagaaggt 1740
accccattgt atgggatctg atctggggcc tcggtgcaca tgctttacat gtgtttagtc 1800
gaggttaaaa aaacgtctag gccccccgaa ccacggggac gtggttttcc tttgaaaaac 1860
acgatgataa gcttgccaca acccgggatc caccggtcgc caccatggtg agcaagggcg 1920
aggagctgtt caccggggtg gtgcccatcc tggtcgagct ggacggcgac gtaaacggcc 1980
acaagttcag cgtgtccggc gagggcgagg gcgatgccac ctacggcaag ctgaccctga 2040
agttcatctg caccaccggc aagctgcccg tgccctggcc caccctcgtg accaccctga 2100
cctacggcgt gcagtgcttc agccgctacc ccgaccacat gaagcagcac gacttcttca 2160
agtccgccat gcccgaaggc tacgtccagg agcgcaccat cttcttcaag gacgacggca 2220
actacaagac ccgcgccgag gtgaagttcg agggcgacac cctggtgaac cgcatcgagc 2280
tgaagggcat cgacttcaag gaggacggca acatcctggg gcacaagctg gagtacaact 2340
acaacagcca caacgtctat atcatggccg acaagcagaa gaacggcatc aaggtgaact 2400
tcaagatccg ccacaacatc gaggacggca gcgtgcagct cgccgaccac taccagcaga 2460
acacccccat cggcgacggc cccgtgctgc tgcccgacaa ccactacctg agcacccagt 2520
ccgccctgag caaagacccc aacgagaagc gcgatcacat ggtcctgctg gagttcgtga 2580
ccgccgccgg gatcactctc ggcatggacg agctgtacaa gtaaagcggc cctagagctc 2640
gctgatcagc ctcgactgtg cctctagttg ccagccatct gttgtttgcc cctcccccgt 2700
gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa atgaggaaat 2760
tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg ggcaggacag 2820
caagggggag gattgggaag acaatagcag gcatgctggg gatgcggtgg gctctatggc 2880
ttctgaggcg gaaagaacca gctggggctc gagtgcattc tagttgtggt ttgtccaaac 2940
tcatcaatgt atcttatcat gtctgtatac cgtcgacctc tagctagagc ttggcgtaat 3000
catggtcata gctgtttcct gtgtgaaatt gttatccgct cacaattcca cacaacatac 3060
gagccggaag cataaagtgt aaagcctggg gtgcctaatg agtgagctaa ctcacattaa 3120
ttgcgttgcg ctcactgccc gctttccagt cgggaaacct gtcgtgccag ctgcattaat 3180
gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc gcttcctcgc 3240
tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg 3300
cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag 3360
gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc 3420
gcccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aacccgacag 3480
gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttccga 3540
ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc 3600
aatgctcacg ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg 3660
tgcacgaacc ccccgttcag cccgaccgct gcgccttatc cggtaactat cgtcttgagt 3720
ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca 3780
gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca 3840
ctagaaggac agtatttggt atctgcgctc tgctgaagcc agttaccttc ggaaaaagag 3900
ttggtagctc ttgatccggc aaacaaacca ccgctggtag cggtggtttt tttgtttgca 3960
agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg 4020
ggtctgacgc tcagtggaac gaaaactcac gttaagggat tttggtcatg agattatcaa 4080
aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta 4140
tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag 4200
cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag ataactacga 4260
tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac ccacgctcac 4320
cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggtc 4380
ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta 4440
gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc gtggtgtcac 4500
gctcgtcgtt tggtatggct tcattcagct ccggttccca acgatcaagg cgagttacat 4560
gatcccccat gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc gttgtcagaa 4620
gtaagttggc cgcagtgtta tcactcatgg ttatggcagc actgcataat tctcttactg 4680
tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag tcattctgag 4740
aatagtgtat gcggcgaccg agttgctctt gcccggcgtc aatacgggat aataccgcgc 4800
cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg cgaaaactct 4860
caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca cccaactgat 4920
cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga aggcaaaatg 4980
ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat actcatactc ttcctttttc 5040
aatattattg aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta 5100
tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagtg ccacctgacg 5160
tc 5162

Claims (10)

1. a kind of for expressing the bacterial strain for being integrated with the recombinant single chain antibody of AIF, it is characterised in that the bacterial strain is by following methods Preparation:
1) sequence Aif-T18 expressing gene as shown in SEQ ID No.2 is taken, is connect by digestion mode with pET302 plasmid, Obtain recombinant plasmid pET302-Aif-T18;
2) the resulting recombinant plasmid pET302-Aif-T18 of step 1) is taken, is transferred in E.coli BL21, obtains recombinant bacterium PET302-Aif-T18-B21, it is as described for expressing the bacterial strain for the recombinant single chain antibody for being integrated with AIF.
2. application claim 1 described in bacterial strain preparation be integrated with AIF recombinant single chain antibody method, it is characterised in that including with Lower step:
A bacterial strain described in claim 1) is taken to access in LB culture medium with ampicillin, 35~39 DEG C of shake cultures are stayed overnight;
B step A) is taken) obtained bacterium solution is cultivated, it is seeded in fresh LB culture medium, is cultivated with the inoculum concentration of 3~7% (v/v) It is 0.6~0.8 to bacterium solution OD value, inducer IPTG to 0.8~1.2mM of final concentration is added, then in 35~39 DEG C of shake cultures 3 ~5h;
C it) is separated by solid-liquid separation and takes precipitating, thallus is resuspended in the Binding Buffer that 20~25mL is added, and ultrasonication, then solid-liquid divides It is precipitated from taking;
D inclusion body) is collected from the step C) sediment, inclusion body is resuspended in the Binding Buffer that 20~25mL is added;
E) take step D) resulting solubilization of inclusion bodies in albuminous degeneration liquid, until wherein final concentration of the 30 of inclusion body protein~ 50mg/mL, room temperature shake 3~5h, are then centrifuged 25~35min with the revolving speed of 12000~14000rpm, take supernatant, by its with The volume ratio of 1:80~1:120 is added into protein renaturation liquid, under agitation, 36~48h is kept in 2~6 DEG C of environment, dense It mixes with His beads by the volume ratio of 1:3~1:5 after contracting, is then eluted using the imidazole solution that concentration is 450~550mM Albumen recycles PBS solution dialysis.
3. according to the method described in claim 2, it is characterized in that step C) described in ultrasonication condition are as follows: at every ultrasound 5s is managed, 8s is stopped, is so repeated 95 times, power 200W, 2 circulations.
4. according to the method described in claim 2, it is characterized in that step C) in second of condition being separated by solid-liquid separation are as follows: 8000~ The revolving speed of 12000rpm is centrifuged 8~12min.
5. according to the method described in claim 2, it is characterized in that step D) described in collect inclusion body, be first to use Triton X-100/EDTA Solution washing precipitating, it is inclusion body that pale precipitation is taken after centrifugation.
6. according to the method described in claim 2, it is characterized in that step D) in Binding Buffer dosage and step C) The dosage of middle Binding Buffer is equal.
7. according to the method described in claim 2, it is characterized in that step E) described in albuminous degeneration liquid be concentration be 7.5~ The urea liquid of 8.5M;The protein renaturation liquid is the urea liquid that concentration is 1.8~2.2M.
8. according to the method described in claim 2, it is characterized in that step E) described in mix stirred under the conditions of 2~6 DEG C Mix 3~5h.
9. according to the method described in claim 2, it is characterized in that step E) continue to execute following operation after the completion: take TEM1 negative Property cell and TEM1 positive cell, it is positive thin using protein product obtained by flow cytomery and TEM1 negative cells, TEM1 The binding ability of born of the same parents;Using protein product obtained by MTT colorimetric determination to the killing energy of TEM1 negative cells, TEM1 positive cell Power.
10. according to the method described in claim 9, it is characterized in that the TEM1 positive cell is to be prepared by the following method :
M) it obtains TEM1 segment: plasmid pCMV6-XL4-TEM1 being taken to obtain TEM1 segment using glue recycling after double digestion;
N) it constructs- 3Zf (-)-TEM1 recombinant plasmid: the TEM1 segment obtained in step m) is connected by digestion Method is connected toIn -3Zf (-) plasmid to get arrive recombinant plasmid-3Zf(-)-TEM1;
O) it constructs- 3Zf (-)-TEM1-Top10 recombinant bacterial strain: step n) is resulting-3Zf(-)-TEM1 Recombinant plasmid is transferred in E.coli Top10, obtains recombinant bacterial strain-3Zf(-)-TEM1-Top10;
P) it constructs pIRES-TEM1-EGFP recombinant plasmid: obtaining from the recombinant bacterial strain obtained in step o) containing TEM1's- 3Zf (-)-TEM1 recombinant plasmid, the method connected by digestion, is connected in pIRES-EGFP plasmid to get arriving Recombinant plasmid pIRES-TEM1-EGFP;
Q) it constructs pIRES-TEM1-EGFP-Top10 recombinant bacterial strain: recombinant plasmid pIRES-TEM1-EGFP is transferred to E.coli In Top10, recombinant bacterial strain pIRES-TEM1-EGFP-Top10 is obtained;
R) it constructs TEM1 positive MS1 cell: rotating into from pIRES-TEM1-EGFP recombinant plasmid electricity is extracted in step q) into TEM1 yin Property cell MS1, screens to obtain TEM1 positive cell line by G418.
CN201611112189.9A 2016-12-07 2016-12-07 For express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain application Active CN106591207B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611112189.9A CN106591207B (en) 2016-12-07 2016-12-07 For express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611112189.9A CN106591207B (en) 2016-12-07 2016-12-07 For express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain application

Publications (2)

Publication Number Publication Date
CN106591207A CN106591207A (en) 2017-04-26
CN106591207B true CN106591207B (en) 2019-10-29

Family

ID=58597201

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611112189.9A Active CN106591207B (en) 2016-12-07 2016-12-07 For express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain application

Country Status (1)

Country Link
CN (1) CN106591207B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060003860A (en) * 2003-03-04 2006-01-11 기린 비루 가부시키가이샤 Endothelial cell specific antibodies and uses thereof
US20100297145A1 (en) * 2005-08-04 2010-11-25 Kazutake Tsujikawa Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent
JP2008199989A (en) * 2007-02-22 2008-09-04 Kazusa Dna Kenkyusho New expression vector for cancer treatment

Also Published As

Publication number Publication date
CN106591207A (en) 2017-04-26

Similar Documents

Publication Publication Date Title
KR102630017B1 (en) Programmed death 1 ligand 1 (PD-L1) binding protein and methods of use thereof
CN112480264B (en) Chimeric antigen receptor taking TIGIT and PD-1 as targets, CAR-T cell and preparation method thereof
US5922685A (en) IL-12 gene therapy of tumors
WO1997046263A9 (en) Il-12 gene therapy of tumors
KR102261586B1 (en) Antibody producing non-human mammals
CN109714962A (en) System and method for cultivating cell in vitro
CN107098969B (en) A kind of recombination structure of Chimeric antigen receptor that treating HIV infection and its application
CN101002936A (en) Vaccine for preventing flavivirus infection
CN110511286B (en) RNA base editing molecule
CN102649947A (en) Cell strain for measuring bioactivity of GLP-1 and functional analogue thereof and application of cell strain
CN1867669B (en) Method for producing gamma-carboxylated proteins
CN113164625A (en) Mutant inverse tetracycline transactivators for gene expression
CA3126839A1 (en) Treatment of diseases involving deficiency of enpp1 or enpp3
CN103773803A (en) Recombined cattle parainfluenza carrier for expressing protein VP1 of porcine O type foot-and-mouth disease virus
CN106591207B (en) For express AIF and be integrated with AIF recombinant single chain antibody bacterial strain and the bacterial strain application
CN111057715B (en) Reverse genetic operation system for rescuing swine seneca virus based on double promoters and establishment method thereof
CN112210543B (en) CAR-T cell for overcoming TGF-beta immunosuppression aiming at solid tumor
CN108059675B (en) Construction of recombinant PG9-CAR molecule and application thereof in eliminating HIV-1 infected cells
CN112501126B (en) CHO-DHFR + cell strain and application thereof
CN109097392A (en) A kind of Her2-CAR-T system constituting method based on PiggyBac carrier
CN108070033A (en) A kind of structure of 3BNC-CAR molecules and its application in HIV-1 infection cells are killed
CN110423736B (en) Base editing tool, application thereof and method for editing wide-window and non-sequence preference bases in eukaryotic cells
KR20220139344A (en) Compositions and methods for treating neurodegenerative diseases
KR102596599B1 (en) Composition for preventing or treating immune diseases comprising mitochondrial localization sequence
CN101280318A (en) Recombinant human HNP gene liposome complex, preparation and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant